| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | See Remarks
1 company
Vittal Vasista last filed a Form 4 in March 2024, as Chief Financial Officer at RGNX. Vittal Vasista's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Vittal Vasista a strong insider score of 79/100, based on 6 past trades. Over a 12-month horizon, all 6 of those trades were profitable, with an average 12-month return of +41.6%.
At the last filing, the largest reported position was 246,534 shares of RGNX. The RGNX filings lean toward selling, a net 385,440 shares.
Vittal Vasista has 58 Form 4 filings on record from September 2015 to March 2024, all as Chief Financial Officer at Regenxbio (RGNX), 2015–2024.
The 121 reported transactions were 83 open-market sales, 20 option exercises, 9 option or other derivative awards and 6 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 40 sales worth about $19.0M.
The largest open-market sale was 73,418 shares of RGNX at an average $70.20 on November 2, 2018, about $5.2M.
Shares as reported in the last Form 4 for each company; the most recent is from March 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 30, 2022 | RGNX Regenxbio Inc. | Chief Financial Officer | Sell | 2,400 | $30.24 | $72,572.64 | -1.7% | -24.1% | -38.4% | |
| Aug 5, 2022 | RGNX Regenxbio Inc. | Chief Financial Officer | Sell | 17,680 | $35.18 | $622,034.82 | -11.4% | -39.9% | -49.5% | |
| Aug 1, 2022 | RGNX Regenxbio Inc. | Chief Financial Officer | Sell | 2,400 | $31.26 | $75,012.00 | -1.5% | -23.7% | -38.3% | |
| Jul 14, 2022 | RGNX Regenxbio Inc. | Chief Financial Officer | Sell | 4,800 | $30.01 | $144,028.16 | -3.0% | -26.1% | -38.0% | |
| Jan 15, 2021 | RGNX Regenxbio Inc. | Chief Financial Officer | Sell | 252 | $50.04 | $12,610.08 | -0.2% | - | - | |
| Jan 14, 2021 | RGNX Regenxbio Inc. | Chief Financial Officer | Sell | 15,293 | $50.02 | $765,024.79 | -11.8% | - | - | |
| Jan 8, 2021 | RGNX Regenxbio Inc. | Chief Financial Officer | Sell | 16,239 | $49.06 | $796,614.87 | -11.2% | - | - | |
| Dec 24, 2020 | RGNX Regenxbio Inc. | Chief Financial Officer | Sell | 24,500 | $50.01 | $1,225,211.24 | -15.6% | - | - | |
| Dec 11, 2020 | RGNX Regenxbio Inc. | Chief Financial Officer | Sell | 37,500 | $40.10 | $1,503,890.76 | -19.2% | - | - | |
| Jul 15, 2020 | RGNX Regenxbio Inc. | Chief Financial Officer | Sale+OE | 14,950 | $40.10 | $599,495.00 | -7.1% | - | - |